AstraZeneca (LSE:AZN) and HUTCHMED reported results from the SANOVO Phase III trial in China evaluating Tagrisso in combination with Orpathys as a first-line treatment for certain patients with non-small cell lung cancer.

The trial showed a statistically significant and clinically meaningful improvement in progression-free survival for the combination compared with Tagrisso alone in treatment-naïve patients with EGFR-mutated, MET-overexpressing non-small cell lung cancer.

The companies also reported trends in overall survival and said the safety profile of the all-oral combination was consistent with previously reported data.

SANOVO evaluates combination in first-line setting

The SANOVO study assessed the Tagrisso-Orpathys combination in patients who had not previously received treatment for EGFR-mutated, MET-overexpressing non-small cell lung cancer.

The results extend the clinical evaluation of the combination into the first-line setting following the Phase III SAFFRON and SACHI trials, which studied the regimen in previously treated patients.

The companies did not provide information in the supplied material regarding regulatory submissions or approvals resulting from the SANOVO findings.

AstraZeneca develops targeted lung cancer therapies

AstraZeneca is a global biopharmaceutical company with operations across oncology and other disease areas, including the development of treatments for lung cancer.

Its lung cancer portfolio includes targeted therapies such as Tagrisso and Orpathys, alongside immunotherapies and other agents being developed for different stages of non-small cell lung cancer.